Hengrui Medicine In-Licenses China Rights to Nausea/Vomiting Drug

Jiangsu Hengrui Medicine in-licensed China rights to an anti-nausea/vomiting drug from Tesaro of the US. The drug, rolapitant, is a neurokinin-1 (NK-1) receptor antagonist currently under NDA review at the FDA, with a PDUFA ruling expected by September 5, 2015. Hengrui will make unspecified upfront and milestone payments, plus pay royalties on net China sales of the drug. Further financial details were not disclosed. More details.... Stock Symbols: (SHA: 600276) (NSDQ: TSRO) Share this with colleagues: // //